僵直性脊椎炎市场规模、份额和成长分析（按药物类别、分销管道和地区）- 产业预测 2025-2032

2023 年全球僵直性脊椎炎市场规模价值 67.8 亿美元，预计将从 2024 年的 72.8 亿美元成长到 2032 年的 128.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.4%。

僵直性脊椎炎的特征是脊椎和关节的慢性炎症，全球僵直性脊椎炎市场呈现成长趋势，这得益于全球盛行率和认知度的上升。诊断方法的改进使得早期发现成为可能，有助于改善治疗效果。医学研究的重大发展促成了非类固醇消炎剂、TNF抑制剂和白细胞介素抑制剂等创新治疗方法的推出，这些治疗方法显着改善了患者的生活品质并推动了市场需求。人口老化，尤其是受影响更频繁的男性，进一步加剧了这种增长。然而，市场面临着诸如由于症状不明显而导致的诊断不足、生物製药成本上升以及某些地区获得医疗保健的机会有限等挑战。此外，由于缺乏永久的治疗方法，因此需要持续的疾病管理，从而影响未来的市场动态。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

僵直性脊椎炎市场规模（依药物类别及复合年增长率） （2025-2032）

• 市场概况
• 非类固醇消炎剂(NSAID)
• TNF 抑制剂
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • 其他 TNF 抑制剂
• 其他药物类别

僵直性脊椎炎市场规模（依分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 其他的

僵直性脊椎炎市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• AbbVie Inc.（United States）
• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB SA（Belgium）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Gilead Sciences Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• AstraZeneca plc（United Kingdom）
• Sanofi SA（France）
• GlaxoSmithKline plc（United Kingdom）
• Horizon Therapeutics plc（Ireland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）
• Zydus Lifesciences Limited（India）
• Izana Bioscience（United Kingdom）

结论和建议

Global Ankylosing Spondylitis Market size was valued at USD 6.78 billion in 2023 and is poised to grow from USD 7.28 billion in 2024 to USD 12.89 billion by 2032, growing at a CAGR of 7.4% during the forecast period (2025-2032).

The global ankylosing spondylitis market, characterized by chronic spinal and joint inflammation, is on a growth trajectory, propelled by rising global prevalence and awareness. Enhanced diagnostic methods enable early detection, contributing to improved treatment outcomes. Key developments in medical research have introduced innovative therapies, including NSAIDs, TNF inhibitors, and interleukin inhibitors, significantly enhancing patient quality of life and amplifying market demand. The aging population, particularly men who are more frequently affected, further fuels this growth. However, the market faces challenges such as underdiagnosis due to ambiguous symptoms, high costs of biologic therapies, and limited healthcare access in certain regions. Additionally, the absence of a permanent cure necessitates ongoing disease management, shaping the future dynamics of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Market Segments Analysis

Global Ankylosing Spondylitis Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Market

Recent progress in medical research has enhanced our comprehension of ankylosing spondylitis, including its root causes and possible treatment options. The introduction of targeted therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, has notably transformed the management of this condition. The accessibility of effective medications, alongside the continuous refinement of treatment guidelines, plays a crucial role in driving the expansion of the global ankylosing spondylitis market. With ongoing advancements in therapeutic strategies and an increasing awareness of the disease, the market is poised for significant growth, addressing the unmet needs of individuals affected by this condition.

Restraints in the Global Ankylosing Spondylitis Market

The global ankylosing spondylitis market faces significant constraints due to the necessity of long-term disease management and ongoing treatment. Effective control of this condition hinges on patients' compliance with medication schedules, commitment to lifestyle changes, and regular medical follow-ups. These factors can pose challenges to consistent patient adherence and effective disease monitoring. As a result, the difficulties associated with sustained management of ankylosing spondylitis may hinder overall market growth, as patients struggle to maintain the necessary regimen for optimal health outcomes. Addressing these compliance issues is crucial for unlocking the potential of the ankylosing spondylitis treatment market.

Market Trends of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is witnessing a significant trend towards early diagnosis and treatment, driven by the increasing recognition of the importance of timely intervention in managing this chronic inflammatory condition. Enhanced diagnostic techniques and heightened awareness among healthcare professionals and patients are contributing to an uptick in early detection rates. This proactive approach fosters prompt initiation of therapies aimed at controlling inflammation, alleviating symptoms, and staving off disease progression. Consequently, patient advocacy organizations and healthcare providers are intensifying educational campaigns, thereby shaping a market landscape that prioritizes optimal patient outcomes and drives demand for innovative treatment modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ankylosing Spondylitis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Non-Steroidal Anti Inflammatory Drug(NSAID)
• TNF Inhibitors
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Other TNF Inhibitors
• Other Drug Classes

Global Ankylosing Spondylitis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market Size & CAGR (2025-2032)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Izana Bioscience (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations